GNBT.OB

[dennis67]

GNBT is overbought and I think it's ready to turn around, when it drops it will go fast. This is my opinion and based on that I'm out for now.I bought 20000 OLGC. Watch GNBT closely if your still in Good LUCK.

stocks2watch YOU ARE UNBELIEVABLE  i sold as soon  as i seen your post  man did it drop how did you no? i wish i could aplaud you  its coming back up now  thans so much for all your  hard work posting on gnbt take care

[rv]

GNBT is overbought and I think it's ready to turn around, when it drops it will go fast. This is my opinion and based on that I'm out for now.I bought 20000 OLGC. Watch GNBT closely if your still in Good LUCK.

just happened to pop over to the streamer and saw that the bid/ask was around 3.60, i thought i was seeing things, opened up the individual streamer and it had dropped so fast, there's no way to have sold....truly hope you guys were able to get out before the dive, or at least that it climbs back up.

[Lucas Scott]

GNBT is overbought and I think it's ready to turn around, when it drops it will go fast. This is my opinion and based on that I'm out for now.I bought 20000 OLGC. Watch GNBT closely if your still in Good LUCK.

Wow Stocks2 you nailed that call! Cliff diver formation on the intraday chart. Probably will retrace to $2.75. OLGC eh? Looks like a good bounce play. Target in the high $2's?

[Kublakhan]

CBMX took a dive the exact same time as GNBT?  Weird.  Difference is that CBMX is now back in the green for the day. 

[rickjust]

hi,
good call stock2.also when the yahoo boards are swimming in euphoria it is  a signal that it is overstretched. there is a good quote about that . i will see if i can find it,
maxi

[rv]

CBMX took a dive the exact same time as GNBT?  Weird.  Difference is that CBMX is now back in the green for the day. 

i also noted that, and actually, you can overlay the daily chart w/ each other and they're basically exact....

[vic666]

stocks2watch3, great call! applauds to you.

i'm not trading GNBT or any other mainstream NASDAQ bird flu stock, but actually bought STTK this afternoon on a pullback at $0.67.

I was quite perplexed when i was following the bird flu sector when GNBT plunged...and if u noticed, all American bird flu stocks got pulled back with GNBT's drop - NVAX, CBMX, AVII, HEB - though not as much as GNBT !!

interestingly, the chinese bird flu play, SVA was unscathed by the american bird flu sector drop, and that gave me some confidence to hold STTK, which came close to breaking uptrend line support levels, but did not (was watching L2 closely for that, i do not like placing stop loss orders, manipulation in BB stocks can kill you).

i loved the close on STTK, at the high of day at $0.73.

about the rest of the bird flu sector, may be it's time for a pullback from several days of unstopped running. the chinsese sector may be a safe place for this week and next. SVA should continue uptrend and hopefully, STTK will too!

[Kublakhan]

People are saying that this article caused the nosedive today

Bird flu can't spread easily in humans: expert

http://trimurl.com/4ST

Good for humanity, bad for our portfolio   

[dez]

Applying the Fibonacci retracement analysis to the plunge today indicates the following.

The recent run from 2.03 up todays high of 5.02 was breathtaking to watch but the inevitable correction occurred.  The folllowing are fibonacci support levels.

62%   -   $3.87
50%   -   $3.52
38%   -   $3.16

Looks to me that the bottom should be in, give or take a nickle.

Same evaluation from the previous advance from $1.40 up to $2.75 indicated a retracement to the 38% level of $2.01.  That level held and a new advance began.  On these type heavy corrections I like to use the three day rule.  Wait three days and buy.  I closed out today at $4.77 and entered at $2.03

[strut1702]

What an AH frenzy with GNBT (Down 20%)over this article by Smartmoney:

http://yahoo.smartmoney.com/undertheradar/index.cfm?story=20060324&afl=yahoo

What is everybody's take?  Very suspicious to be released so late.  Predictions for Mon?  Anybody still long on Oral-Lyn?

[gambler2075]

It's probably not going to get there (2.50), but I am looking for a continuation of the selloff AH on monday... and I may reenter. Too hard to tell now.

g

[LiveLife]

Very nice job Generex management!   

Antigen working with FDA to fast-track flu vaccine

March 24, 2006

Antigen working with FDA to fast-track flu vaccine

http://www.generex.com/news-management/templates/press.asp?articleid=249&zoneid=2

BY KEITH REGAN
SPECIAL TO THE JOURNAL

WORCESTER - Antigen Express Inc. hopes to begin early-stage clinical trials as early as this fall on a synthetic peptide vaccine that could be made simply, quickly and in large quantities to help prepare for a possible avian flu pandemic.

The Worcester firm met last month with the U.S. Food and Drug Administration and said the federal agency gave it clear instructions for moving ahead in the approval process for its vaccine - a road map that could have Antigen Express filing an Investigational New Drug application with the FDA within a matter of weeks.

"The FDA was uncharacteristically outgoing," said Eric yon Hafe, president of the eight-person firm, a wholly owned subsidiary of Toronto-based Generex Biotechnology Corp. (Nasdaq: GNBT). "They made it clear what they wanted to see from us."

The United States has seen flu vaccine shortages in recent years, and there is widespread concern that should an avian flu pandemic hit it could take years to produce enough vaccine through traditional means, which involve growing the drugs in eggs or cell cultures.

"We could produce it on a 100-kilogram scale at anyone of a number of contract manufacturers we work with. It's conceivable we could produce enough to vaccinate the majority ofthe U.S. population," said von Hofe.

Concern about an avian flu pandemic continues to mount. Last year, Congress set aside $3.8 billion to aid in preparedness, and several agencies have taken steps to speed production of new treatments, tests and vaccines. According to the Centers for Disease Control, human cases of the avian flu have now been confirmed in 37 countries, with 175 people infected and 96 dead.

At least one other firm, San Diego based Vicallnc. (Nasdaq: VI CL), is working to develop an alternative avian flu vaccine-production method using bacteria to produce its DNA vaccine.

In early March, the FDA issued guidelines clarifying the data it wants from vaccine makers. Acting FDA Commissioner Dr. Andrew von Eschenbach said that move "illustrates FDAs high level of commitment and key role in preparing for influenza pandemic, which is a top priority for our nation."

The FDA created an accelerated approval pathway for the vaccine Fluarix, used to prevent type A and B influenza, in 2005. A new lab test that reduces the time it takes to confirm avian flu from days to hours was also approved on an expedited schedule, with the FDA using what von Eschenbach called "flexible regulatory authorities."

Von Hofe hopes his firm's applicalions will benefit from that flexibility and from regulators' desire to have more vaccines in the pipeline.
Antigen Express intends to finish pre-clinical toxicity tests by late summer and is designing Phase I trials.

Antigen Express was founded in 1994 based on work von Hofe and Dr. Robert Humphries did at University of Massachusetts Medical School. Generex purchased the firm in 2003.

[setravis]

Hot...Hot...Hot ! 

Will get even hotter...
Long term buy along with GNTA.
I've already made gains in both, and feel that there is much room for even more gains.IMHO..

Donald Luskin has this marked one as a bird flu play and it looks to be in a nice uptrend. Loose stop on this one, The pullback is probably a nice entry.

Canadian company producing vaccines against the bird flu epidemic.
Read today where the flu is growing in Europe and Asia.
Projections are that the US mainland will have cases of the Bird Flu this Summer.
If this happens,Watch for this stock to move higher......jmho.
See little overhead resistance as it continues to make new multi-year highs....

I'm hanging tight...."Kick me in the rear if I'm wrong!"

News from Feb. 28,2006.......States

Generex Biotechnology Corporation (NasdaqSC:GNBT - News) announced today that it has received an aggregate of $11 million as a result of the exercise by existing Company investors of previously issued warrants. The receipt of these funds has put the Company's cash-on-hand at more than $31 million, its strongest cash position in more than four years.

The Smartmoney article of just yesterday.....States.....
"For the past year, Generex hasn't been able to pay off its debt." and
In July, its auditors also expressed "substantial doubt" about the company's ability to continue as a going concern given its losses, negative cash flow from operations and dearth of working capital.

Makes one wonder why they omitted the information from the 2-28-2006 article.


Technicals
Most Actives

Last Price Quote is:
23.38%above 13-day EMA
77.77%above 50-day EMA
RS Rating: 99 

Fundamentals
Key Data:
Market Cap (M): $186.79 
P/E Ratio: NA 
PEG Ratio: N/A 
Next Earnings: N/A
Last Analyst Rating: Buy

[LiveLife]

= Confirmation!!! =

The shorts are at it again!  No wonder, the shorts want GNBT to go down in price.

Shorts will be BIG losers on Monday as they all try to cover on Monday!!!   

http://www.knobias.com/individual/public/news.htm?eid=3.1.c662e32b6ef71c96bb09d6e4c0cc7a7fbe219d082c2c1b714326334ac8f8f672

Friday , March 24, 2006 16:18 ET

According to new short interest data from NASDAQ, short interest for Generex Biotechnology Corporation (NasdaqSC: GNBT) INCREASED 46.6% to 2,593,556 shares for the month ended mid-March, 2006.

SYMBOL          FEBRUARY           MARCH          CHANGE       %CHANGE  DAYS/COVER
--------   -------------   -------------   -------------  ------------  ----------
GNBT           1,768,736       2,593,556        +824,820       +46.63%           1

Based on GNBT's 20-day average daily share volume of 19,794,915, it would require approximately 1 day(s) of buying to cover this short interest.



Wow, this is eye opening!  Thanks creekrat88 for the post from Yahoo MB.

Kinda, makes some sense as to what goes on at the stock market place.  There's a discussion on Yahoo MB as to how much of this still goes on.  Makes you ponder.  Hmmmmm. 

03/23/06 08:51 pm
Msg: 148620 of 148790

http://www.thestreet.com/_yahoo/stocks/brokerages/10273590.html?cm_ven=YAHOO&cm_cat=FREE&cm_ite=NA

Hedge Fund Shells Out in Shorting Probe

By Matthew Goldstein
Senior Writer
3/14/2006 2:19 PM EST
Click here for more stories by Matthew Goldstein

A New York hedge fund manager will pay $16 million to settle allegations arising out of a two-year-old investigation into manipulative trading in the market for private placements by small-cap companies.

The penalty agreed to by Jeffrey Thorp is the largest settlement assessed to date by the Securities and Exchange Commission in the investigation into trading abuses in the $18 billion-a-year market for PIPEs, or private investment in public equity.

The PIPEs investigation is focusing on allegations of abusive short-selling by hedge funds trying to take advantage of the usual decline in shares of companies that sell these deals.

A short-sale is a market bet that a stock will decline in price.

Securities regulators, in a civil complaint filed in federal court as part of the settlement, charged Thorp with carrying out an illegal short-selling scheme involving 23 separate PIPE deals from 2000 to 2002. Regulators allege Thorp profited by engaging in "naked shorting,'' a manipulative practice that enables traders to defy the laws of supply and demand by shorting even when no shares are available to borrow.

In all, the SEC contends, Thorp generated $7 million in illicit profits from his illegal shorting scheme. As part of the settlement, Thorp agreed to forfeit those profits, plus $1.8 million interest. Thorp and his Langley Partners hedge fund agreed to pay $8 million in civil penalties.

The unlawful trading by Thorp, who could not be reached for comment, took place in PIPE deals by a number of well-known biotech firms: AVI BioPharma (AVII:Nasdaq), MGI Pharma (MOGN:NYSE) and Generex Biotechnology (GNBT:Nasdaq). Other PIPEs that regulators allege Thorp manipulated were ones by HealthExtras (HLEX:Nasdaq) and TiVo (TIVO:Nasdaq).[/b]

"This case is an example of our ongoing effort to stamp out fraud and abuses by investors in the PIPEs market, and it will continue,'' says Scott Friestad, associate director in the SEC's enforcement division.

The SEC contends Thorp carried out the naked-shorting scheme with the assistance of an unidentified Canadian broker. Over the years, critics of the PIPEs market often have alleged that U.S. hedge funds were carrying out abusive trading strategies in Canada, where the rules against naked shorting were less stringent.

A year ago, U.S. securities regulators, in part because of the PIPEs investigation, took steps to make it more difficult for traders to engage in naked shorting in this country. Friestad says he believes Canada has taken a similar action.

Regulators say the naked shorting scheme was critical to Thorp's strategy because it enabled him to make short bets on the shares of companies doing PIPE deals, even when no shares were available for him to borrow from a broker in the U.S. The naked shorting, according the complaint, enabled Thorp to "earn larger profits'' when a stock declined in price because he "had no borrowing limitations.''

In other words, the illegal strategy gave Thorp a big advantage over other investors in these PIPE deals who used legal means to short shares as a hedge against a decline in the price.

In a typical short sale, a trader borrows shares from a broker, sells them, and then hopes the stock falls so he can replace his borrowed stock at a lower price. The short-seller makes money by pocketing the difference between the borrowed shares he sold and the ones he purchased.

But in a naked short sale, a trader places short bets without actually borrowing the stock first, or even determining that any shares are available to borrow. This way, naked short-sellers are freed from a key check of the short-sale process -- the need to find willing stock lenders. Critics claim such operations create excessive downward pressure on certain stocks and can create chaos as buyers await undeliverable shares.

Left unchecked, naked shorting can lead to an anomalous situation in which the total number of shares sold short on a stock exceeds its float, or the number of shares available for trading.


On a similar note, here's some more info on the "not so straight" stock market:

The Associated Press/NEW YORK

http://www.businessweek.com/ap/financialnews/D8GG5SIOF.htm?campaign_id=apn_home_down&chan=db

Day traders accused in securities scheme

MAR. 21 3:12 P.M. ET Several former and current officers, directors, and managers of a Manhattan day trading firm were charged Tuesday in a superseding indictment with participating in a "front-running" securities fraud scheme that generated more than $800,000 in illegal profits, prosecutors said.

New charges were filed against Robert F. Malin, vice chairman and president of A.B. Watley Group Inc., and Linus Nwaigwe, the company's director of compliance and a former National Association of Securities Dealers compliance examiner; Michael A. Picone, Watley's former chief operating officer, and Keevan H. Leonard, Watley's former supervisor of proprietary trading.

Also named in the superseding indictment were several people originally indicted in August 2005. They include Kenneth E. Mahaffy, Jr., a former Merrill Lynch & Co. and Citigroup Global Markets Inc. stock broker; Timothy J. O'Connell, a former Merrill stock broker; and David G. Ghysels, Jr., a former Lehman Brothers stock broker.

In addition to the criminal charges, the Securities and Exchange Commission filed a civil complaint against Malin, Nwaigwe, Picone and Leonard.

"Front-running" occurs when stock brokers inform traders outside the brokerage firm, such as day traders, that a customer of the brokerage firm has placed a large order to buy or sell a particular stock, prosecutors said. The information allows day traders to trade in the same stock before the customer's order is executed, in anticipation of a movement in price. As a result, the firm's customers often do not obtain as favorable a price as they might have.

Steven Scaring, counsel for Mahaffy, has not seen the new indictment yet, but expects that his client will plead not guilty to it as he did to the original indictment.

"We will try to get this case tried as soon as possible. Mr. Mahaffy fully expects to be vindicated," Scaring said.

O'Connell's lawyer, Mildred Whalen, also said she hadn't seen the superseding indictment. "But it is my understanding that there are no new charges against Mr. O'Connell, that the new indictment added on defendents," she said.

Attorneys representing Ghysels, Malin, Nwaigwe, Picone and Leonard were unavailable for comment.

The superseding indictment unsealed Tuesday alleges that between January 2002 and February 2004, Mahaffey, O'Connell, Ghysels and Coughlin routinely provided day traders at three New York City-based day trading firms with customer order information, which was disseminated through internal speaker systems, known as "squawk boxes."

Some of the brokers also accepted cash bribes from the day traders in exchange for squawk box access, prosecutors said.

The superseding indictment alleges that the day traders profited from the scheme by trading ahead of the large orders that were broadcast through the squawk boxes. When the squawk boxes disseminated information concerning a large sell order for a particular stock, the day traders would "short sell" the same securities before the larger order was executed.

Either way, the day traders profited from the movement in price, prosecutors said.

"By bribing unscrupulous stock brokers, the former A.B. Watley managers and day traders who were charged today were able to secretly tap into a steady flow of extremely valuable, confidential information from some of Wall Street's most well known institutions," U.S. Attorney Roslynn Mauskopf said in a statement.

Prosecutors also announced Tuesday that Paul F. Coughlin, another former Merrill broker, and William B. Deakins, a former Watley day trader, pleaded guilty to related charges of conspiracy to commit securities fraud for their roles in the scheme. Ralph D. Casbarro, another former Citigroup broker, pleaded guilty to conspiracy to commit securities fraud last October.

Attorneys for Coughlin and Deakins were also unavailable for comment.

[snowcat]

http://www.ceocast.com/(l40bidvzc2pvmb55dxkiqufp)/NewsLetters.aspx?id=334&mode=

This article kind of counters the Smart Money article, FWIW.

Looks like another worthless stock and a lot of bagholders.